Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome

J Allergy Clin Immunol. 2011 Dec;128(6):1352-4. doi: 10.1016/j.jaci.2011.05.023. Epub 2011 Jun 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Autoimmune Diseases / drug therapy*
  • Female
  • Hereditary Autoinflammatory Diseases / drug therapy*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Interleukin-1 / antagonists & inhibitors*
  • Interleukin-1beta / metabolism*
  • Schnitzler Syndrome / drug therapy*
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Interleukin-1beta
  • Tumor Necrosis Factor-alpha